Target Information

Target General Infomation
Target ID
T15739
Former ID
TTDC00118
Target Name
Cellular tumor antigenp53
Gene Name
TP53
Synonyms
Antigen NY-CO-13; P53; Phosphoprotein p53; Tumor suppressor p53; TP53
Target Type
Clinical Trial
Disease Acute myeloid leukemia [ICD9: 205; ICD10: C92.0]
Cancer [ICD9: 140-229; ICD10: C00-C96]
Colorectal cancer [ICD9: 153, 154; ICD10: C18-C21]
Head and neck cancer [ICD9: 140-149, 140-229; ICD10: C07-C14, C32-C33]
Hematological malignancies [ICD9: 200-209; ICD10: C81-C86]
Late-stage solid tumors [ICD9: 140-199, 210-229; ICD10: C00-C75, C7A, C7B, D10-D36, D3A]
Oral cavity cancer [ICD10: C00-C08]
Renal artery disease [ICD10: I70.1]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
Toxicity [ICD10: T36-T50, T51-T65]
Unspecified [ICD code not available]
Function
Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division.
BioChemical Class
Pore-forming pnc-27 peptide of 32 aas
Target Validation
T15739
UniProt ID
P04637
Sequence
MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGP
DEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAK
SVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHE
RCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNS
SCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELP
PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPG
GSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
Drugs and Mode of Action
Drug(s) Contusugene ladenovec Drug Info Phase 3 Oral cavity cancer [521522]
ALT-801 Drug Info Phase 2 Acute myeloid leukemia [531657]
INGN-225 Drug Info Phase 2 Head and neck cancer [547762]
ISA-P53-01 Drug Info Phase 1/2 Colorectal cancer [551047]
QPI-1002 Drug Info Phase 1/2 Renal artery disease [522509]
CGM097 Drug Info Phase 1 Late-stage solid tumors [524175]
Dendritic cell vaccine Drug Info Phase 1 Head and neck cancer [521923]
HDM201 Drug Info Phase 1 Hematological malignancies [524765]
ONYX-015 Drug Info Phase 1 Head and neck cancer [521477]
SAR-405838 Drug Info Phase 1 Cancer [549401]
SGT-53 Drug Info Phase 1 Solid tumours [525080]
Thioureidobutyronitrile Drug Info Phase 1 Solid tumours [548744]
APR-246 Drug Info Preclinical Cancer [548912]
INGN-234 Drug Info Discontinued in Phase 2 Oral cavity cancer [548784]
Ad-p53 Drug Info Discontinued in Phase 1 Cancer [545815]
Pifithrin-alpha Drug Info Terminated Toxicity [547076]
TAR-1 Drug Info Terminated Cancer [548982]
Inhibitor 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Drug Info [551374]
HDM201 Drug Info [550513]
NU-8231 Drug Info [528471]
NUTLIN-3 Drug Info [530476]
Pifithrin-alpha Drug Info [527750]
Modulator Ad-p53 Drug Info [526572]
ALT-801 (bolus injection), Altor Drug Info [531657]
CGM097 Drug Info [1572591]
Contusugene ladenovec Drug Info [529934]
ONYX-015 Drug Info [525928], [527347]
QPI-1002 Drug Info [1572591]
SAR-405838 Drug Info [532926]
Thioureidobutyronitrile Drug Info [549682]
Immunomodulator (Immunostimulant) ALT-801 Drug Info [531657]
Stimulator APR-246 Drug Info [525399]
SGT-53 Drug Info [532257]
Suppressor INGN-234 Drug Info [551122]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
DRM DRM Info
Pathways
KEGG Pathway MAPK signaling pathway
Sphingolipid signaling pathway
Cell cycle
p53 signaling pathway
PI3K-Akt signaling pathway
Apoptosis
Wnt signaling pathway
Neurotrophin signaling pathway
Thyroid hormone signaling pathway
Amyotrophic lateral sclerosis (ALS)
Huntington&#039
s disease
Hepatitis C
Hepatitis B
Measles
HTLV-I infection
Herpes simplex infection
Epstein-Barr virus infection
Pathways in cancer
Transcriptional misregulation in cancer
Viral carcinogenesis
Proteoglycans in cancer
MicroRNAs in cancer
Colorectal cancer
Pancreatic cancer
Endometrial cancer
Glioma
Prostate cancer
Thyroid cancer
Basal cell carcinoma
Melanoma
Bladder cancer
Chronic myeloid leukemia
Small cell lung cancer
Non-small cell lung cancer
Central carbon metabolism in cancer
NetPath Pathway FSH Signaling Pathway
PANTHER Pathway Apoptosis signaling pathway
Huntington disease
Wnt signaling pathway
p53 pathway
P53 pathway feedback loops 1
p53 pathway by glucose deprivation
p53 pathway feedback loops 2
Pathway Interaction Database Signaling events mediated by HDAC Class III
Validated targets of C-MYC transcriptional activation
LKB1 signaling events
Glucocorticoid receptor regulatory network
Direct p53 effectors
p75(NTR)-mediated signaling
AP-1 transcription factor network
Hypoxic and oxygen homeostasis regulation of HIF-1-alpha
Signaling mediated by p38-alpha and p38-beta
Aurora A signaling
BARD1 signaling events
p53 pathway
PLK3 signaling events
Reactome Activation of NOXA and translocation to mitochondria
Activation of PUMA and translocation to mitochondria
Pre-NOTCH Transcription and Translation
Oxidative Stress Induced Senescence
Formation of Senescence-Associated Heterochromatin Foci (SAHF)
Oncogene Induced Senescence
DNA Damage/Telomere Stress Induced Senescence
Autodegradation of the E3 ubiquitin ligase COP1
TP53 Regulates Metabolic Genes
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
Stabilization of p53
Factors involved in megakaryocyte development and platelet production
WikiPathways DNA Damage Response (only ATM dependent)
DNA Damage Response
ErbB Signaling Pathway
Senescence and Autophagy in Cancer
G1 to S cell cycle control
Sandbox Pathway
Wnt Signaling Pathway and Pluripotency
MAPK Signaling Pathway
TGF beta Signaling Pathway
Copper homeostasis
Bladder Cancer
Mammary gland development pathway - Involution (Stage 4 of 4)
Pre-NOTCH Expression and Processing
Apoptosis
ATM Signaling Pathway
Amyotrophic lateral sclerosis (ALS)
Retinoblastoma (RB) in Cancer
Spinal Cord Injury
Integrated Pancreatic Cancer Pathway
Oncostatin M Signaling Pathway
Gastric cancer network 2
Prostate Cancer
Signaling Pathways in Glioblastoma
Metastatic brain tumor
Alzheimers Disease
Integrated Breast Cancer Pathway
Integrated Cancer pathway
Intrinsic Pathway for Apoptosis
Factors involved in megakaryocyte development and platelet production
Cell Cycle
Cell Cycle Checkpoints
Apoptosis Modulation and Signaling
Folate Metabolism
TP53 Network
Fluoropyrimidine Activity
miRNAs involved in DNA damage response
miRNA Regulation of DNA Damage Response
AMPK Signaling
References
Ref 521477ClinicalTrials.gov (NCT00006106) ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer. U.S. National Institutes of Health.
Ref 521522ClinicalTrials.gov (NCT00041613) Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate. U.S. National Institutes of Health.
Ref 521923ClinicalTrials.gov (NCT00404339) Vaccine Therapy in Treating Patients With Head and Neck Cancer. U.S. National Institutes of Health.
Ref 522509ClinicalTrials.gov (NCT00802347) I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation. U.S. National Institutes of Health.
Ref 524175ClinicalTrials.gov (NCT01760525) A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 524765ClinicalTrials.gov (NCT02143635) Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt. U.S. National Institutes of Health.
Ref 525080ClinicalTrials.gov (NCT02354547) A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors. U.S. National Institutes of Health.
Ref 531657Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75.
Ref 545815Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004882)
Ref 547076Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012866)
Ref 547762Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019096)
Ref 548744Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028294)
Ref 548784Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028790)
Ref 548912Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030246)
Ref 548982Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031168)
Ref 549401Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036509)
Ref 551047Clinical pipeline report, company report or official report of ISA Pharmaceuticals BV.
Ref
Ref 525399APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881. doi: 10.1038/cddis.2013.417.
Ref 525928Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000 Nov 15;60(22):6359-66.
Ref 526572Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 2003 Mar;10(3):224-38.
Ref 526975Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004 Jul;53(7):633-41. Epub 2004 Feb 25.
Ref 527347Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004 Dec;6(6):611-23.
Ref 527750An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines. Mol Cancer Ther. 2005 Sep;4(9):1369-77.
Ref 528471J Med Chem. 2006 Oct 19;49(21):6209-21.Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.
Ref 529934A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther. 2009 Feb;11(1):54-61.
Ref 530476J Med Chem. 2009 Nov 26;52(22):7044-53.Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.
Ref 530870INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-91.
Ref 531657Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75.
Ref 532257Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr;20(4):222-8.
Ref 532926SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014 Oct 15;74(20):5855-65.
Ref 544333Regulation of host gene expression by HIV-1 TAR microRNAs. Retrovirology. 2013; 10: 86.
Ref 549682J Clin Oncol 31, 2013 (suppl; abstr TPS2627).
Ref 550172WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
Ref 550513National Cancer Institute Drug Dictionary (drug id 761551).
Ref 551122Prevent Oral Cancer With Mouthwash. Introgen Therapeutics.
Ref 551374The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.